Skip to Menu Skip to Search Contact Us Global Websites & Languages Skip to Content

About

This webinar will help you uncover strategies for managing risks specific to the cosmetics and personal care industry during the COVID-19 health crisis.

Starts

April 30, 2020, 09:00

Ends

April 30, 2020, 10:00

Location

Online

To help fight the battle against COVID-19, SGS is working to ensure that we are doing everything possible to protect people and businesses.

As a cosmetics and personal care goods producer, you must be prepared to tackle the challenges that your industry faces during this unprecedented situation. This webinar will show you how to manage risk during the COVID-19 pandemic and how you can upgrade your skills, while adhering to travel restrictions, with our virtual training options.

Objective

To discuss strategies for managing risks to the cosmetics and personal care industry during the COVID-19 pandemic:

  • Risk assessments
  • First, second and third-party certification
  • Training opportunities
  • Cleaning and sanitizing processes during the outbreak

Agenda

  • Conducting risk assessments and mitigating risk
    • Raw material origin
    • Supply chain requirements
    • Operations
    • Updating your cleaning and sanitizing processes during the COVID-19 crisis
    • Using remote auditing to maintain your third-party certification scheme
  • Turning crisis into opportunity – how to upgrade your skills with our virtual training options

Target Audience

Quality manager, regulatory managers, compliance managers, QA employees, and all those involved in production management.

Date/Time: April 30, 2020 | 11:00-12:00 pm EST

Cost: No Charge
Language: English

Presenter

Jennifer Lott – Technical Director – Pharmaceuticals, Cosmetics, and Personal Care

Register >

 

SGS Next Normal Solutions

The COVID-19 pandemic is unprecedented in the modern era, posing unforeseen challenges to business continuity. At SGS, we are working hard to meet those challenges and support international efforts to beat COVID-19.

Find out more about our Next Normal Solutions >